Terumo Angio-Seal VIP, Инструкция по эксплуатации

Страница: 3 / 13

2
ADVERSE EVENTS
7KH$QJLR6HDOŒGHYLFHZDVHYDOXDWHGLQDQRQUDQGRPL]HGFOLQLFDOWULDOLQYROYLQJSDWLHQWVLQZKRPWKHDFFHVVVLWHVZHUHFORVHGZLWKWKHGHYLFHIROORZLQJGLDJQRVWLFDQJLRJUDSK\
Q RUSHUFXWDQHRXVFRURQDU\LQWHUYHQWLRQQ SURFHGXUHV7DEOHUHSRUWVWKHDGYHUVHHYHQWVDVDSHUFHQWDJHRISDWLHQWVZKRUHFHLYHGWKH$QJLR6HDOGHYLFHLQWKHFOLQLFDO
LQYHVWLJDWLRQ
Table 1: Percentage of Patients Experiencing Adverse Events
Adverse Event 8F/6F
Diagnostic
(n=97)
8F
Interventional
(n=106)
6F
Interventional
(n=103)
Minor Complication
+HPDWRPD!FP
,QIHFWLRQZRKRVSLWDOL]DWLRQ
)DOVHDQHXU\VPZRLQWHUYHQWLRQ
AV Fistula
Deep Vein Thrombosis
Vasovagal Response
Device Non-Deployment
Device Malfunction
Major Complication
Vascular Repair
/DWH*,EOHHGLQJUHTXLULQJWUDQVIXVLRQ ‚
,QIHFWLRQZKRVSLWDOL]DWLRQ
)DOVHDQHXU\VPUHTXLULQJLQWHUYHQWLRQ
'97UHTXLULQJLQWHUYHQWLRQ
$9)LVWXODUHTXLULQJLQWHUYHQWLRQ
5HWURSHULWRQHDOEOHHGLQJUHTXLULQJLQWHUYHQWLRQ
Any Complication ‡ Á
Major Complication
2QHSDWLHQWKDGKHPDWRPD!FPFRPELQHGZLWK'97
1RWGHYLFHUHODWHG
‚3DWLHQWDOVRH[SHULHQFHGDKHPDWRPDFP
Á1RWLQFOXGLQJGHYLFHQRQGHSOR\PHQWV
1RGHDWKVRFFXUUHGGXULQJWKHVWXG\
%DVHGRQFOLQLFDOH[SHULHQFHWKHIROORZLQJGHVFULEHVSRVVLEOHWUHDWPHQWVIRUULVNVRUVLWXDWLRQVWKDWDUHDVVRFLDWHGZLWKXVHRIWKH$QJLR6HDOGHYLFHRUYDVFXODUDFFHVVSURFHGXUHV
• %OHHGLQJRUKHPDWRPD $SSO\OLJKWGLJLWDORUPDQXDOSUHVVXUHWRWKHSXQFWXUHVLWH,IPDQXDOSUHVVXUHLVQHFHVVDU\PRQLWRUSHGDOSXOVHV
• $9ILVWXODRUSVHXGRDQHXU\VP ,IVXVSHFWHGWKHFRQGLWLRQPD\EHHYDOXDWHGZLWKGXSOH[XOWUDVRXQG:KHQLQGLFDWHGXOWUDVRXQGJXLGHGFRPSUHVVLRQRIDSVHXGRDQHXU\VPPD\EH
XVHGDIWHUWKH$QJLR6HDOGHYLFHKDVEHHQSODFHG
• 'HYLFHQRQGHSOR\PHQW ,IGHYLFHSXOOVRXWZLWKVKHDWKXSRQZLWKGUDZDODSSO\PDQXDORUPHFKDQLFDOSUHVVXUHSHUVWDQGDUGSURFHGXUH([DPLQHWKHGHYLFHWRHQVXUHDOODEVRUEDEOH
FRPSRQHQWVKDYHEHHQZLWKGUDZQ
• $QFKRUIUDFWXUHRUHPEROLVP ([DPLQHGHYLFHWRGHWHUPLQHLIDQFKRUKDVEHHQZLWKGUDZQ,IEOHHGLQJRFFXUVDSSO\PDQXDORUPHFKDQLFDOSUHVVXUHWRWKHSXQFWXUHVLWHSHUVWDQGDUG
SURFHGXUHV,IDQFKRULVQRWDWWDFKHGWRWKHGHYLFHPRQLWRUWKHSDWLHQWIRUDWOHDVWKRXUVIRUVLJQVRIYDVFXODURFFOXVLRQ&OLQLFDOH[SHULHQFHWRGDWHLQGLFDWHVWKDWWLVVXHLVFKHPLD
IURPDQHPEROL]HGDQFKRULVXQOLNHO\6KRXOGLVFKHPLFV\PSWRPVDSSHDUWUHDWPHQWRSWLRQVLQFOXGHWKURPERO\VLVSHUFXWDQHRXVH[WUDFWLRQRIWKHDQFKRURUIUDJPHQWVRUVXUJLFDO
LQWHUYHQWLRQ
• ,QIHFWLRQ $Q\VLJQRILQIHFWLRQDWWKHSXQFWXUHVLWHVKRXOGEHWDNHQVHULRXVO\DQGWKHSDWLHQWPRQLWRUHGFDUHIXOO\6XUJLFDOUHPRYDORIWKHGHYLFHVKRXOGEHFRQVLGHUHGZKHQHYHUDQ
DFFHVVVLWHLQIHFWLRQLVVXVSHFWHG
• &ROODJHQGHSRVLWLRQLQWRWKHDUWHU\RUWKURPERVLVDWSXQFWXUHVLWH ,IWKLVFRQGLWLRQLVVXVSHFWHGWKHGLDJQRVLVFDQEHFRQILUPHGE\GXSOH[XOWUDVRXQG7UHDWPHQWRIWKLVHYHQWPD\
LQFOXGHWKURPERO\VLVSHUFXWDQHRXVWKURPEHFWRP\RUVXUJLFDOLQWHUYHQWLRQ
• 9HU\WKLQSDWLHQWV &ROODJHQPD\SURWUXGHIURPWKHVNLQDIWHUWDPSLQJKDVEHHQFRPSOHWHG$WWHPSWWRSXVKWKHFROODJHQXQGHUWKHVNLQXVLQJWKHWDPSHUWXEHRUDVWHULOHKHPRVWDW
'2127DSSO\YLJRURXVWDPSLQJDVWKLVPD\UHVXOWLQDQFKRUIUDFWXUH'2127FXWRIIWKHH[FHVVFROODJHQDVWKHVXWXUHZRYHQWKURXJKWKHFROODJHQPD\EHFXWDQGWKHLQWHJULW\RI
WKHDQFKRUFROODJHQVDQGZLFKFRXOGEHFRPSURPLVHG
• 2EHVHSDWLHQWV 7KHWDPSHUWXEHPD\QRWEHORQJHQRXJKWREHH[SRVHGRUJUDVSHGDWWKHVNLQ3ODFHILQJHUVRQHLWKHUVLGHRIWKHVXWXUHFRPSUHVVWKHVXUURXQGLQJWLVVXHDQG
DWWHPSWWRH[SRVHWKHWDPSHUWXEH,IQHFHVVDU\DVWHULOHKHPRVWDWPD\EHXVHGWRJUDVSWKHWDPSHUWXEHVRWKHFROODJHQFDQEHWDPSHGDGHTXDWHO\
7KHIROORZLQJSRWHQWLDODGYHUVHUHDFWLRQVRUFRQGLWLRQVPD\DOVREHDVVRFLDWHGZLWKRQHRUPRUH$QJLR6HDOGHYLFHFRPSRQHQWVLHFROODJHQV\QWKHWLFDEVRUEDEOHVXWXUHDQGRU
V\QWKHWLFDEVRUEDEOHSRO\PHU
• Allergic reaction
• Foreign body reaction
• Potentiation of infection
• Inflammation
‡ (GHPD